Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

161. Variability in response to antipsychotics and placebo in schizophrenia: a systematic review and meta-analysis

Variability in response to antipsychotics and placebo in schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

162. Clozapine dosing and titration in schizophrenia and their impact on tolerability and response: a systematic review

Clozapine dosing and titration in schizophrenia and their impact on tolerability and response: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

163. An association between brexpiprazole dose and the improvement of psychopathology in patients of schizophrenia

An association between brexpiprazole dose and the improvement of psychopathology in patients of schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

164. Comparison of completed and attempted suicide rates among the patients withschizophrenia and schizophrenia-like psychosis receiving anti-psychotictreatment: protocol for anetwork meta-analysis

Comparison of completed and attempted suicide rates among the patients withschizophrenia and schizophrenia-like psychosis receiving anti-psychotictreatment: protocol for anetwork meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2018 PROSPERO

165. Meta-analysis of cross-sectional social cognition and neurocognition with functional outcomes in schizophrenia disorders: an update

Meta-analysis of cross-sectional social cognition and neurocognition with functional outcomes in schizophrenia disorders: an update Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

166. Investigating the efficacy of n-acetylcysteine as an adjunct treatment for schizophrenia: a meta-analytic review

Investigating the efficacy of n-acetylcysteine as an adjunct treatment for schizophrenia: a meta-analytic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

167. What is the prevalence of treatment-resistance schizophrenia? A systematic review and meta-analysis

What is the prevalence of treatment-resistance schizophrenia? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

168. Commonly altered peripheral protein markers in drug-na?ve first-episode patients with either schizophrenia or major depressive disorder

Commonly altered peripheral protein markers in drug-na?ve first-episode patients with either schizophrenia or major depressive disorder Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

169. ECT combined with clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials

ECT combined with clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

170. A systematic review of symptomatic trajectories and profiles in patients with schizophrenia based on group-based trajectory modeling approach

A systematic review of symptomatic trajectories and profiles in patients with schizophrenia based on group-based trajectory modeling approach Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

171. Cariprazine (Reagila) for the treatment of schizophrenia

Cariprazine (Reagila) for the treatment of schizophrenia Cariprazine (Reagila®) for the treatment of schizophrenia | Report | National Health Care Institute You are here: Cariprazine (Reagila®) for the treatment of schizophrenia Search within English part of National Health Care Institute Search Cariprazine (Reagila®) for the treatment of schizophrenia The Minister of Health, Welfare and Sport (WVS) asked Zorginstituut Nederland (National Health Care Institute) to carry out a substantive (...) assessment of the medicinal product Reagila® to determine whether it can be included in the Medicine Reimbursement System (GVS). And if so, if Cariprazine (Reagila®) is interchangeable with a medicinal product that is already included in the GVS. Advice Reagila® is an atypical antipsychotic, registered for the treatment of schizophrenia in adult patients. Based on the criteria for interchangeability, the Zorginstituut concludes that Reagila® is interchangeable with drugs that are already included

2018 National Health Care Institute (Zorginstituut Nederland)

172. Adjunctive ondansetron for schizophrenia: a meta-analysis of randomized controlled trials

Adjunctive ondansetron for schizophrenia: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

173. A comparison of psychopathology between smokers and non-smokers with schizophrenia: a systematic review and meta-analysis of comparative studies

A comparison of psychopathology between smokers and non-smokers with schizophrenia: a systematic review and meta-analysis of comparative studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

174. The effects of transcranial direct current stimulation on working memory in patients with schizophrenia

The effects of transcranial direct current stimulation on working memory in patients with schizophrenia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

175. Schizophrenia spectrum and other psychotic disorders and co-morbid opioid use disorder (OUD) - Outcomes of opioid substitution treatment (OST): A Systematic Review

Schizophrenia spectrum and other psychotic disorders and co-morbid opioid use disorder (OUD) - Outcomes of opioid substitution treatment (OST): A Systematic Review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2018 PROSPERO

176. Retinal changes in schizophrenia patients: a systematic review and meta-analysis

Retinal changes in schizophrenia patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

177. Gender-sensitivity in research on social exclusion in individuals with a diagnosis of Schizophrenia or Schizoaffective disorder: a systematic review

Gender-sensitivity in research on social exclusion in individuals with a diagnosis of Schizophrenia or Schizoaffective disorder: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

178. Standardized neuropsychological tests of effort in schizophrenia and other psychotic disorders: a systematic review and meta-analysis

Standardized neuropsychological tests of effort in schizophrenia and other psychotic disorders: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

179. Folic acid for schizophrenia: a systematic review and meta-analysis

Folic acid for schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

180. White matter and cognitive functions in schizophrenia: a systematic review and meta-analysis

White matter and cognitive functions in schizophrenia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO